share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lurker Nancy

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lurker Nancy

EyePoint Pharmaceuticals | 4:持股變動聲明-高管 Lurker Nancy
美股sec公告 ·  07/12 17:07
Moomoo AI 已提取核心訊息
EyePoint Pharmaceuticals, Inc. (EYPT) has reported a completed transaction involving Executive Vice Chair Nancy Lurker. On July 10, 2024, Lurker acquired 11,111 shares of EyePoint Pharmaceuticals' common stock at no cost, as part of an exercise or conversion of a derivative security. Following this transaction, Lurker directly holds a total of 94,462 shares. Additionally, there is an indirect holding of 126,889 shares by a family trust associated with Lurker. The transaction reflects a strengthening of Lurker's investment in the company and may be of interest to current and potential investors.
EyePoint Pharmaceuticals, Inc. (EYPT) has reported a completed transaction involving Executive Vice Chair Nancy Lurker. On July 10, 2024, Lurker acquired 11,111 shares of EyePoint Pharmaceuticals' common stock at no cost, as part of an exercise or conversion of a derivative security. Following this transaction, Lurker directly holds a total of 94,462 shares. Additionally, there is an indirect holding of 126,889 shares by a family trust associated with Lurker. The transaction reflects a strengthening of Lurker's investment in the company and may be of interest to current and potential investors.
EyePoint Pharmaceuticals公司(eyepoint pharmaceuticals)報告了一筆已完成的交易,涉及執行副董事長Nancy Lurker。2024年7月10日,Lurker以零成本方式收購了11,111股EyePoint Pharmaceuticals普通股,作爲衍生證券行權或轉換的一部分。此次交易後,Lurker直接持有總計94,462股。此外,與Lurker有關的家庭信託間接持有126,889股。這筆交易反映了Lurker在公司中的投資加強,可能對現有和潛在投資者感興趣。
EyePoint Pharmaceuticals公司(eyepoint pharmaceuticals)報告了一筆已完成的交易,涉及執行副董事長Nancy Lurker。2024年7月10日,Lurker以零成本方式收購了11,111股EyePoint Pharmaceuticals普通股,作爲衍生證券行權或轉換的一部分。此次交易後,Lurker直接持有總計94,462股。此外,與Lurker有關的家庭信託間接持有126,889股。這筆交易反映了Lurker在公司中的投資加強,可能對現有和潛在投資者感興趣。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息